CEO Lynn Seely said Lyell Immunopharma Inc. is going “full steam ahead” with development of rondecabtagene autoleucel (ronde-cel, also known as LYL-314) amid the excitement of the firm’s latest news: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback